Verastem, Inc. (VSTM)

Verastem Oncology is a biopharmaceutical company built on a specific scientific bet: that patients with cancers driven by mutations in the RAS/MAPK signaling pathway will benefit from drugs that block those pathways. The company is not profitable yet, does not expect to be for some time, and runs almost entirely on the economics of late-stage drug development—gambling cash reserves on clinical trials in hopes of eventually selling medicines that generate far more in lifetime revenue than the company invested to discover and prove them.

“A cancer drug either works and changes your business, or it fails and you have nothing.” The entire company hinges on whether its pipeline moves from trials to approval to meaningful patient adoption.

Revenue: one drug, early stages

Verastem has a single marketed drug: AVMAPKI FAKZYNJA CO-PACK, a combination of two molecules (avutometinib and defactinib) that won accelerated approval from the FDA for patients with KRAS-mutated, recurrent, low-grade serous ovarian cancer who have failed prior treatment. Accelerated approval means the FDA allowed the drug to reach patients on the strength of early data in a small population, but the company must keep proving its worth in larger studies or the approval could be withdrawn. Product revenue from this drug was approximately $31 million for the full year 2025, which sounds substantial until you remember that the company’s R&D and clinical-trial spending is in the hundreds of millions. The drug generates enough revenue to defer some burn, but it does not come close to funding the company’s pipeline work.

The pipeline and the unit economics of drug development

Verastem’s real bet is on VS-7375, an oral inhibitor of KRAS G12D (a specific cancer-driving mutation) that the company licensed and took over development of in early 2025. The company is running Phase 1/2 dose-escalation and combination trials in patients with KRAS G12D solid tumors, with larger registration-directed Phase 2 trials in pancreatic cancer, non-small-cell lung cancer, and colorectal cancer. The company expects early data in the first half of 2026 and more mature data in the latter half. If VS-7375 works and wins approval, it could address a much larger patient population than the ovarian-cancer niche that FAKZYNJA serves, which would dramatically expand revenue—or it could fail in trials, in which case months of burn and sunk investment yield nothing.

This is the unit economics of biotech: a company spends tens to hundreds of millions developing a drug, facing roughly a 90 percent probability of failure before launch and a significant risk of failure even after approval. On the 10 percent of programs that do succeed, a successful drug can generate a billion dollars or more in annual sales. The company that gets one winner may recoup all its losses across all its bets. The company that gets too many losers goes bankrupt.

Capital structure and the cash runway problem

Verastem ended the first quarter of 2026 with cash and investments of approximately $182 million, a reasonable runway for a clinical-stage biotech with modest revenue, but clinical development can be expensive and unpredictable. A major setback in the KRAS program—failed trial, safety signal, competitive loss—would accelerate cash burn and force the company to raise capital or cut costs. Biotech companies that dilute shareholders through equity raises are common; companies that survive on cash without dilution are rare. Shareholders are betting that the company’s burn rate will stay manageable and that revenue from FAKZYNJA plus success in one or more pipeline programs will get the company to profitability or acquisition before cash runs out.

Competitive landscape and the moat in biology

Verastem is not alone in pursuing KRAS-targeted drugs; several large pharma companies are in the space, with more capital and more diversified portfolios. Verastem’s advantage is focus and early-mover status in specific indications and patient populations. If VS-7375 succeeds in its target cancers before competitors launch and establish themselves, Verastem could capture market share and license revenue or acquisition interest from larger pharma companies wanting to add the drug to their portfolios. If competitors move faster or deliver superior efficacy, Verastem’s drugs could be relegated to niche roles or displaced entirely.

What moves the stock

Clinical-stage biotech stocks are driven almost entirely by news about trial data, regulatory decisions, and cash runway. Positive interim data lifts the stock; trial failures or unmet endpoints cause sharp declines. Approvals, licensing deals, and strategic partnerships drive upside; competitive moves, regulatory setbacks, and news of failed development programs create downside. The stock can be volatile because the binary nature of drug development means good news is very good and bad news can be catastrophic.

How to research Verastem

Start with the company’s 10-K and quarterly 10-Q filings (SEC CIK 0001526119), which lay out the drug pipeline, the development stage of each program, and cash burn and runway. The pipeline slide on the investor website and the latest clinical trial results are essential reading. Listen to quarterly earnings calls to hear management’s assessment of trial progress, competitive positioning, and capital needs. For context, follow the major oncology conferences where trial data is presented and compare Verastem’s data to what competitors are claiming. The key question is whether VS-7375 and any other pipeline programs are on track for success, and whether the company’s cash is sufficient to reach meaningful milestones without significant additional capital raises that would dilute shareholders.